About this trial
Rationale: Investigate if there is a significant weight reduction expressed in total body weight loss percentage (%TBWL) in patients 5 years after surgery, whom underwent a mini gastric bypass (MGB-OAGB) with addition of the implantation of a MiniMizer Ring.
Study design: A prospective non blinded single centre randomized controlled trial.
Sudy population: The study population will exist of patients eligible for MGB-OAGB surgery. Patients are invited to participate if Body Mass Index (BMI) ≥ 35kg/m2 with a comorbidity related to morbid obesity, or a BMI exceeding 40kg/m2.
Intervention: Insertion of the MiniMizer Ring around the gastric pouch in addition to the 'standard' MGB-OAGB.
Main study parameters/endpoints:
Primary Objective:
1. %TBWL 5 years after surgery.
Secondary Objectives: 2. Percentage Excess Weight Loss (%EWL) 5 years after surgery. 3. Decrease or reduction of comorbidities (diabetes mellitus, hypertension, hyperlipidemia, sleep apnoea, and joint complaints). 4. Improvement of quality of life: SF-36 and OBESI-Q questionnaires. 5. Incidence and severity of dumping syndrome. 6. Incidence and severity of reflux symptoms: GERD-HRQoL questionnaire. 7. Incidence and complications due to silicone band.
Measurement of objectives are before surgery and six times after surgery combined with the standard postoperative care for patients who undergo bariatric surgery:
Expected advantages of bOLGB versus OLGB:
1. Increase of weight reduction, and due to that decrease of comorbidities and/or mortality related to overweight. 2. Long term decrease of weight regain. 3. Decrease of incidence of dumping.
Possible disadvantages of bOLGB versus OLGB:
1. Band-related complications such as erosion, infection, stenosis, or pouch dilatation. 2. Functional gastro-intestinal complains such as dysphagia and reflux.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients meet IFSO criteria for Bariatric Surgery
Age 18 and above
Disqualifiers
Previous Bariatric surgery
Inability to read and understand written information
Any genetic condition that can hamper the acceptance of medical advice
chronic bowel disease
Trial design
Parallel
Treatments tested in this trial
Placement of MiniMizer Gastric Ring
DeviceInsertion of MiniMizer Gastric Ring in addition to the normal MGB-OAGB
Normal MGB-OAGB
Procedure/SurgeryNo insertion of Minimizer Gastric Ring in addition to the normal MGB-OAGB
Treatment groups
Trial outcomes
Primary outcomes
Total Body Weight Change 5 years after surgery
Percentage total body weight change 5 years after the procedure
Secondary outcomes
Change in Percentage Excess Weight (%EWL) 5 years after surgery
Change in Percentage Excess Weight (%EWL)
Change in (existing) co-morbidities 5 years after surgery
Change in severity of obesity-related co-morbidities: Type 2 Diabetes Mellitus (changes in HbA1c or use of antidiabetic medication), Hypertension (changes in bloodpressure or changes in use of antihypertensives), Osteo-arthritis (changes in VAS-score or use of analgesia drugs) , Hyperlipidemia (changes in HDL/LDL ratio, triglycerides or use of statine drugs), Obstructive Sleep Apnea syndrome (changes in use of CPEP treatment or changes is apneu hypopneu idex), and Gastro-Esophageal Reflux Disease (Changes in outcomes of GERD-HR questionnnaire which scoring scale runs from 0 (asymptomatic) to 50 (complete prohibitive) or changes in use of protonpompinhibitors)
Outcome measurement of SF-36 questionnaire
Evalution of changes in outcome of SF-36 Questionnaire 5 years after surgery. Scoring scale is described between 0 (lowest) and 100 (highest) to evaluate patient's welfare
Outcome measurement of OBESI-Q questionnaire
Evalution of changes in outcome of OBESI-Q Questionnaire 5 years after surgery. Scoring scale is described between 0 (lowest) and 100 (highest) to evaluate patient's welfare
Sponsors and contacts
Click on the lead sponsor to view all of their trials.